JP2018531625A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531625A5 JP2018531625A5 JP2018532523A JP2018532523A JP2018531625A5 JP 2018531625 A5 JP2018531625 A5 JP 2018531625A5 JP 2018532523 A JP2018532523 A JP 2018532523A JP 2018532523 A JP2018532523 A JP 2018532523A JP 2018531625 A5 JP2018531625 A5 JP 2018531625A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding protein
- recombinant antigen
- antigen binding
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims description 33
- 108091000831 antigen binding proteins Proteins 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 230000008499 blood brain barrier function Effects 0.000 claims description 5
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 239000012216 imaging agent Substances 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 229960002224 eculizumab Drugs 0.000 claims 1
- 229960000578 gemtuzumab Drugs 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229960005267 tositumomab Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 229950009904 pritumumab Drugs 0.000 description 4
- -1 scFv Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021127980A JP2021191269A (ja) | 2015-09-11 | 2021-08-04 | 脳への向上した薬物送達の方法 |
| JP2023104613A JP7361980B2 (ja) | 2015-09-11 | 2023-06-27 | 脳への向上した薬物送達の方法 |
| JP2023172056A JP2024001124A (ja) | 2015-09-11 | 2023-10-03 | 脳への向上した薬物送達の方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562217608P | 2015-09-11 | 2015-09-11 | |
| US62/217,608 | 2015-09-11 | ||
| US201562247490P | 2015-10-28 | 2015-10-28 | |
| US62/247,490 | 2015-10-28 | ||
| PCT/US2016/051128 WO2017044866A2 (en) | 2015-09-11 | 2016-09-09 | Enhanced delivery of drugs to the brain |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021127980A Division JP2021191269A (ja) | 2015-09-11 | 2021-08-04 | 脳への向上した薬物送達の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018531625A JP2018531625A (ja) | 2018-11-01 |
| JP2018531625A5 true JP2018531625A5 (enExample) | 2019-10-17 |
Family
ID=58236547
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532523A Pending JP2018531625A (ja) | 2015-09-11 | 2016-09-09 | 脳への向上した薬物送達の方法 |
| JP2021127980A Pending JP2021191269A (ja) | 2015-09-11 | 2021-08-04 | 脳への向上した薬物送達の方法 |
| JP2023104613A Active JP7361980B2 (ja) | 2015-09-11 | 2023-06-27 | 脳への向上した薬物送達の方法 |
| JP2023172056A Pending JP2024001124A (ja) | 2015-09-11 | 2023-10-03 | 脳への向上した薬物送達の方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021127980A Pending JP2021191269A (ja) | 2015-09-11 | 2021-08-04 | 脳への向上した薬物送達の方法 |
| JP2023104613A Active JP7361980B2 (ja) | 2015-09-11 | 2023-06-27 | 脳への向上した薬物送達の方法 |
| JP2023172056A Pending JP2024001124A (ja) | 2015-09-11 | 2023-10-03 | 脳への向上した薬物送達の方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11028155B2 (enExample) |
| EP (2) | EP4548979A3 (enExample) |
| JP (4) | JP2018531625A (enExample) |
| AU (2) | AU2016319133B2 (enExample) |
| CA (1) | CA2998132A1 (enExample) |
| IL (1) | IL257983A (enExample) |
| WO (1) | WO2017044866A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018531625A (ja) | 2015-09-11 | 2018-11-01 | ナセント バイオテック インコーポレイテッド | 脳への向上した薬物送達の方法 |
| US11492394B1 (en) * | 2021-10-29 | 2022-11-08 | Nascent Biotech, Inc. | Kits and containers for treating vimentin expressing tumors |
| CA3236114A1 (en) * | 2021-10-29 | 2023-05-04 | Nascent Biotech, Inc. | Kits and containers for treating vimentin expressing tumors |
| CN114181972A (zh) * | 2021-11-23 | 2022-03-15 | 上海本导基因技术有限公司 | 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| DE3223885A1 (de) | 1982-06-26 | 1983-12-29 | Basf Ag, 6700 Ludwigshafen | Makroporoese, hydrophile traeger fuer enzyme |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5004697A (en) * | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5651991A (en) | 1987-10-28 | 1997-07-29 | Nippon Shinyaku Co. Ltd. | Drug carriers |
| US5994392A (en) | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US20020099179A1 (en) | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| KR940003548U (ko) | 1992-08-14 | 1994-02-21 | 김형술 | 세탁물 건조기 |
| DK0640622T3 (da) | 1993-02-26 | 2000-10-23 | Drug Delivery System Inst Ltd | Polysaccharidderivat og lægemiddelbærer |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| PL182237B1 (pl) | 1994-03-07 | 2001-11-30 | Dow Chemical Co | Sposób przeprowadzania transfekcji komórek i osiagniecia biodostepnosci materialu genetycznego in vitro i ex vivo PL PL |
| US5786387A (en) | 1994-03-23 | 1998-07-28 | Meiji Seika Kabushiki Kaisha | Lipid double-chain derivative containing polyoxyethylene |
| JP3699141B2 (ja) | 1994-09-24 | 2005-09-28 | 伸彦 由井 | 超分子構造の生体内分解性医薬高分子集合体及びその調製方法 |
| US5490840A (en) | 1994-09-26 | 1996-02-13 | General Electric Company | Targeted thermal release of drug-polymer conjugates |
| DE4440337A1 (de) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6106866A (en) | 1995-07-31 | 2000-08-22 | Access Pharmaceuticals, Inc. | In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| WO2000037504A2 (en) | 1998-12-23 | 2000-06-29 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| MXPA02010507A (es) * | 2000-04-25 | 2003-05-14 | Idec Pharma Corp | Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central. |
| US20040126829A1 (en) | 2001-12-18 | 2004-07-01 | Hildebrand William H. | Anti-HLA assay and methods |
| AU2004297616B2 (en) * | 2003-12-04 | 2008-12-18 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| BRPI0607579A2 (pt) | 2005-03-23 | 2009-09-15 | Pfizer Prod Inc | uso de anticorpo anti-ctla4 e indolinona para a preparação de medicamentos para o tratamento de cáncer |
| HRP20150307T1 (hr) * | 2006-09-10 | 2015-04-24 | Glycotope Gmbh | Upotreba ljudskih stanica podrijetlom iz ljudske leukemije za eksprimiranje protutijela |
| WO2013055404A1 (en) * | 2011-10-10 | 2013-04-18 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| EP4219536A3 (en) * | 2012-04-30 | 2023-08-23 | Biocon Limited | Targeted/immunomodulatory fusion proteins and methods for making same |
| US20150218280A1 (en) * | 2012-08-10 | 2015-08-06 | University Of Southern California | CD20 scFv-ELPs METHODS AND THERAPEUTICS |
| GB201220242D0 (en) * | 2012-11-09 | 2012-12-26 | Fusion Antibodies Ltd | Antibody |
| JP2018531625A (ja) | 2015-09-11 | 2018-11-01 | ナセント バイオテック インコーポレイテッド | 脳への向上した薬物送達の方法 |
-
2016
- 2016-09-09 JP JP2018532523A patent/JP2018531625A/ja active Pending
- 2016-09-09 US US15/261,725 patent/US11028155B2/en active Active
- 2016-09-09 AU AU2016319133A patent/AU2016319133B2/en active Active
- 2016-09-09 EP EP24202128.5A patent/EP4548979A3/en active Pending
- 2016-09-09 WO PCT/US2016/051128 patent/WO2017044866A2/en not_active Ceased
- 2016-09-09 CA CA2998132A patent/CA2998132A1/en active Pending
- 2016-09-09 EP EP16845201.9A patent/EP3347380B1/en active Active
-
2018
- 2018-03-08 IL IL257983A patent/IL257983A/en unknown
-
2021
- 2021-03-10 US US17/198,029 patent/US20210269513A1/en active Pending
- 2021-08-04 JP JP2021127980A patent/JP2021191269A/ja active Pending
-
2023
- 2023-06-27 JP JP2023104613A patent/JP7361980B2/ja active Active
- 2023-09-07 AU AU2023226718A patent/AU2023226718A1/en active Pending
- 2023-10-03 JP JP2023172056A patent/JP2024001124A/ja active Pending